Human Genome Epidemiology Literature Finder
|
Records 1 - 17 (of 17 Records) |
| Query Trace: Diarrhea and PIK3CA[original query] |
|---|
| Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer. Breast cancer research and treatment 2014 12 149 (1): 151-61. Tolaney Sara, Burris Howard, Gartner Elaina, Mayer Ingrid A, Saura Cristina, Maurer Matthew, Ciruelos Eva, Garcia Agustin A, Campana Frank, Wu Bin, Xu Yi, Jiang Jason, Winer Eric, Krop I |
| A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Nov . Ma Cynthia X, Luo Jingqin, Naughton Michael, Ademuyiwa Foluso O, Suresh Rama, Griffith Malachi, Griffith Obi L, Skidmore Zachary, Spies Nicholas C, Ramu Avinash, Trani Lee, Pluard Timothy, Nagaraj Gayathri, Thomas Shana N, Guo Zhanfang, Hoog Jeremy, Han Jing, Mardis Elaine R, Lockhart A Craig, Ellis Matthew |
| A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma. Clinical colorectal cancer 2016 Mar . Bowles Daniel W, Kochenderfer Mark, Cohn Allen, Sideris Lucas, Nguyen Nghia, Cline-Burkhardt Vivian, Schnadig Ian, Choi Minsig, Nabell Lisle, Chaudhry Arvind, Ruxer Robert, Ucar Antonio, Hausman Diana, Walker Luke, Spira Alexander, Jimeno Anton |
| Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors. Cancer discovery 2017 Mar . Juric Dejan, Krop Ian, Ramanathan Ramesh K, Wilson Timothy R, Ware Joseph A, Sanabria Bohorquez Sandra, Savage Heidi, Sampath Deepak, Salphati Laurent, Lin Ray, Jin Huan, Parmar Hema, Hsu Jerry Y, Von Hoff Daniel D, Baselga Jo |
| Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer. Cancer science 2018 Jun . Osumi Hiroki, Shinozaki Eiji, Mashima Tetsuo, Wakatsuki Takeru, Suenaga Mitsukuni, Ichimura Takashi, Ogura Mariko, Ota Yumiko, Nakayama Izuma, Takahari Daisuke, Chin Keisho, Miki Yoshio, Yamaguchi Kens |
| A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors. Investigational new drugs 2018 Apr . Aghajanian Carol, Bell-McGuinn Katherine M, Burris Howard A, Siu Lillian L, Stayner Lee-Ann, Wheler Jennifer J, Hong David S, Kurkjian Carla, Pant Shubham, Santiago-Walker Ademi, Gauvin Jennifer L, Antal Joyce M, Opalinska Joanna B, Morris Shannon R, Infante Jeffrey |
| Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor-positive advanced breast cancer. Cancer science 2018 3 109 (5): 1592-1601. Tamura Kenji, Kodaira Makoto, Shimizu Chikako, Yonemori Kan, Yunokawa Mayu, Shimomura Akihiko, Kobayashi Takayuki, Nakano Kenji, Tomomatsu Junichi, Ito Yoshinori, Tanaka Jun, Kuriki Hiroshi, Gu Zhaodi, Takahashi Shun |
| Phosphatidylinositol 3-Kinase ?-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018 2 36 (13): 1291-1299. Juric Dejan, Rodon Jordi, Tabernero Josep, Janku Filip, Burris Howard A, Schellens Jan H M, Middleton Mark R, Berlin Jordan, Schuler Martin, Gil-Martin Marta, Rugo Hope S, Seggewiss-Bernhardt Ruth, Huang Alan, Bootle Douglas, Demanse David, Blumenstein Lars, Coughlin Christina, Quadt Cornelia, Baselga Jo |
| Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. The New England journal of medicine 2019 5 380 (20): 1929-1940. André Fabrice, Ciruelos Eva, Rubovszky Gabor, Campone Mario, Loibl Sibylle, Rugo Hope S, Iwata Hiroji, Conte Pierfranco, Mayer Ingrid A, Kaufman Bella, Yamashita Toshinari, Lu Yen-Shen, Inoue Kenichi, Takahashi Masato, Pápai Zsuzsanna, Longin Anne-Sophie, Mills David, Wilke Celine, Hirawat Samit, Juric Dejan, |
| Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer. The oncologist 2020 12 26 (4): 290-e545. van Brummelen Emilie M J, Huijberts Sanne, van Herpen Carla, Desar Ingrid, Opdam Frans, van Geel Robin, Marchetti Serena, Steeghs Neeltje, Monkhorst Kim, Thijssen Bas, Rosing Hilde, Huitema Alwin, Beijnen Jos, Bernards Rene, Schellens J |
| FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2020 11 27 (7): 1842-1849. Narayan Preeti, Prowell Tatiana M, Gao Jennifer J, Fernandes Laura L, Li Emily, Jiang Xiling, Qiu Junshan, Fan Jianghong, Song Pengfei, Yu Jingyu, Zhang Xinyuan, King-Kallimanis Bellinda L, Chen Wei, Ricks Tiffany K, Gong Yutao, Wang Xing, Windsor Katherine, Rhieu Steve Y, Geiser Gerlie, Banerjee Anamitro, Chen Xiaohong, Reyes Turcu Francisca, Chatterjee Deb K, Pathak Anand, Seidman Jeffrey, Ghosh Soma, Philip Reena, Goldberg Kirsten B, Kluetz Paul G, Tang Shenghui, Amiri-Kordestani Laleh, Theoret Marc R, Pazdur Richard, Beaver Julia |
| Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86). Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Jan . Dhani Neesha C, Hirte Hal W, Wang Lisa, Burnier Julia V, Jain Angela, Butler Marcus O, Welch Stephen, Fleming Gini F, Hurteau Jean, Matsuo Koji, Matei Daniela, Jimenez Waldo, Johnston Carolyn, Cristea Mihaela, Tonkin Katia, Ghatage Prafull, Lheureux Stephanie, Mehta Anjali, Quintos Judy, Tan Qian, Kamel-Reid Suzanne, Ludkovski Olga, Tsao Ming-Sound, Wright John J, Oza Amit |
| Efficacy and Safety of Combination Treatment With Apatinib and Osimertinib After Osimertinib Resistance in Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Carcinoma-A Retrospective Analysis of a Multicenter Clinical Study. Frontiers in molecular biosciences 2021 5 8 639892. Yang Xue, Xia Yang, Xu Liyan, Liang Li, Zhuo Minglei, Wu Meina, An Tongtong, Wang Ziping, Wang Yuyan, Li Jianjie, Zhong Jia, Chen Hanxiao, Jia Bo, Wang Jingjing, Zhao J |
| Neoadjuvant Trastuzumab and Pyrotinib for Locally Advanced HER2-Positive Breast Cancer (NeoATP): Primary Analysis of a Phase II Study. Clinical cancer research : an official journal of the American Association for Cancer Research 2022 6 28 (17): 3677-3685. Yin Wenjin, Wang Yaohui, Wu Ziping, Ye Yumei, Zhou Liheng, Xu Shuguang, Lin Yanping, Du Yueyao, Yan Tingting, Yang Fan, Zhang Jie, Liu Qiang, Lu Jinso |
| Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. JCO precision oncology 2022 2 6 e2100424. Krop Ian E, Jegede Opeyemi A, Grilley-Olson Juneko E, Lauring Josh D, Mitchell Edith P, Zwiebel James A, Gray Robert J, Wang Victoria, McShane Lisa M, Rubinstein Larry V, Patton David, Williams P Mickey, Hamilton Stanley R, Kono Scott A, Ford James M, Garcia Agustin A, Sui Xingwei D, Siegel Robert D, Slomovitz Brian M, Conley Barbara A, Arteaga Carlos L, Harris Lyndsay N, O'Dwyer Peter J, Chen Alice P, Flaherty Keith |
| Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2024 9 JCO2400110. Komal L Jhaveri, Melissa K Accordino, Philippe L Bedard, Andrés Cervantes, Valentina Gambardella, Erika Hamilton, Antoine Italiano, Kevin Kalinsky, Ian E Krop, Mafalda Oliveira, Peter Schmid, Cristina Saura, Nicholas C Turner, Andrea Varga, Sravanthi Cheeti, Stephanie Hilz, Katherine E Hutchinson, Yanling Jin, Stephanie Royer-Joo, Ubong Peters, Noopur Shankar, Jennifer L Schutzman, Dejan Jur |
| Ipatasertib plus Paclitaxel for patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial. Clinical cancer research : an official journal of the American Association for Cancer Research 2024 7 . Rebecca A Dent, Sung-Bae Kim, Mafalda Oliveira, Carlos Barrios, Joyce O'Shaughnessy, Steven J Isakoff, Shigehira Saji, Ruffo Freitas-Junior, Manuel Philco, Igor Bondarenko, Qinshu Lian, Denise Bradley, Heather Hinton, Matthew J Wongchenko, Sarah-Jayne Reilly, Nicholas Turn |
- Page last reviewed:Feb 1, 2024
- Content source: